Bernstein Harold sold $446K of MAZE
Bernstein Harold (President, R&D & CMO) sold 16,142 shares of Maze Therapeutics, Inc. (MAZE) at $27.61 ($0.45M total) on 2026-08-13 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosed event is an open-market sale by an officer under a pre-arranged Rule 10b5-1 plan; without additional company news, it is mainly sentiment and positioning information.
Market read
Traders may monitor MAZE for follow-on insider activity, but the filing alone does not provide a new fundamental catalyst.
What to watch
The article does not state whether the sale was part of a scheduled tranche size relative to prior plans, nor does it provide total insider holdings beyond the post-transaction zero shares.
Background
The article is a SEC Form 4 insider transaction disclosure for Maze Therapeutics, Inc.
Ticker impact
Maze Therapeutics disclosed via Form 4 that President, R&D & CMO Harold Bernstein sold 16,142 shares at $27.6063 on 2026-08-13.
Likely limited near-term impact; traders may view it as routine 10b5-1 selling rather than a fundamental signal.
The filing is a primary-source insider transaction, but the article provides no accompanying company-specific news (guidance, trial results, deals) that would change fundamentals.
Market effects
Minimal; single-company insider sale does not imply sector-wide regulatory or clinical changes.
None indicated.
None indicated.
Counterpoint
Even with a 10b5-1 plan, large insider sales can still coincide with private information or portfolio rebalancing; some traders may treat it as a mild bearish signal.
Key entities
- issuerMaze Therapeutics, Inc.
Subject of the Form 4 insider transaction disclosure.
- insiderHarold Bernstein
President, R&D & CMO who sold 16,142 shares at $27.6063.
- trading mechanismRule 10b5-1 plan
Indicates the sale was pre-arranged, often reducing interpretive weight.